Letter to the Editor -Osteopontin Levels in Human Asthma
Dear Sir Osteopontin (Opn) is a multifunctional cytokine, originally characterized as a Th1 immune response mediator that has only recently been implicated in Th2 mediated diseases 1 . In a recent publication in your journal, Zhao et al. 2 examined serum Opn levels in patients with mild, moderate and severe asthma and investigated possible correlations with disease severity. Opn was found to be significantly higher in all three asthma patient groups compared with healthy controls, while no association was observed between Opn concentration and disease severity. The authors concluded that this study was the first to demonstrate increased Opn serum levels in asthmatics, suggesting a role for this protein in the pathogenesis of asthma. Members of our group have been focusing on the role of Opn in allergic diseases and asthma for a long time and have several publications in the field. 3 -6 In our latest Opn-related publication, 6 which appeared online more than a year ago (18 June 2010), Opn expression was investigated in healthy controls and patients with mild, moderate and severe asthma in steady state and in cases of exacerbation. Levels of Opn in the serum, bronchoalveolar lavage fluid and bronchial tissue were determined and compared to those of healthy controls. The study demonstrated that Opn levels are increased in the serum of asthmatics, without any correlation with disease severity. Additionally, serum Opn was found to be decreased during asthma exacerbations. The findings of Zhao et al. 2 are interesting in the context of confirming our previous results in a different ethnic population with asthma of varying severity. However, failing to reference our previous work and stating that this is the first report is rather misleading. Furthermore, Zhao et al. 2 
